Cognitive‐Behavioral Treatment of Nonalcoholic Fatty Liver Disease: A Propensity Score‐Adjusted Observational Study
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The effectiveness of cognitive‐behavior treatment (CBT) in nonalcoholic fatty liver disease (NAFLD), largely related to overweight/obesity and considered the hepatic expression of the metabolic syndrome (MS), has so far been tested in very limited samples. In a tertiary referral center, consecutively observed NAFLD subjects were offered a CBT program aimed at weight loss and increased physical activity, based on 13 group sessions; 68 cases entered the treatment protocol, those who refused (n = 82) were given recommendations for diet and physical activity. Treatment goals (weight loss ≥7% initial body weight, normalization of liver enzymes, and improved parameters of MS) were tested by logistic regression at 6 months (all cases) and at 2 years, both on intention‐to‐treat and in completers (Diet, 78; CBT, 65). The results were adjusted for the propensity score of attending the CBT program, based on civil, anthropometric and clinical variables. At baseline the CBT group had a larger prevalence of obesity and more severe insulin resistance (homeostasis model assessment (HOMA)). At follow‐up, CBT was associated with a higher probability of weight loss and normal liver enzymes (6‐month: odds ratio (OR), 2.56; 95% confidence interval (CI), 1.15–5.69; 2‐year intention‐to‐treat: OR, 3.57, 95% CI, 1.59–8.00), after adjustment for propensity and changes in body weight. A similar trend was observed in the outcome goals of insulin resistance and the score of MS, which were both reduced. In conclusion, subjects with NAFLD participating in a CBT program significantly improve their general and liver parameters. The beneficial effects are largely maintained at 2‐year follow‐up, in keeping with the lifestyle‐related pathogenesis of disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“CBT has been extensively investigated in metabolic diseases, namely in obesity (27), in subjects at risk (14,15) or with overt diabetes in the community (28), as well as in subjects with mild hypertension to prevent progression to organ disease (16).”
BackgroundLong-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302 · cited 1×
“The high prevalence of associated metabolic disorders and additional features of MS explains why patients with NAFLD are also at significant risk for cardiovascular disease (6), which in most series dictates prognosis more than liver disease progression.”
BackgroundReduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
The Look AHEAD Research Group (2007) · Diabetes Care · doi:10.2337/dc07-0048 · Cited by 1,522
Updated definitions of healthy ranges for serum alanine aminotransferase levels
Prati, D., Taioli, E., Zanella, A., Torre, E. D., Butelli, S., Del Vecchio, E., Vianello, L., Zanuso, F., Mozzi, F., Milani, S., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00006 · Cited by 1,445 · cited 3×
“Effects on liver enzymes levels were largely confirmed by the sensitivity analysis having the updated healthy ranges of ALT (26) as dependent variable.”
BackgroundMethodInfluentialRandomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330
Rubin, D. B. (2007) · Statistics in Medicine · doi:10.1002/sim.2739 · Cited by 1,047
Orchard, T. J., Temprosa, M., Goldberg, R., Haffner, S., Ratner, R., Marcovina, S., Fowler, S., & for the Diabetes Prevention Program Research Group (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-8-200504190-00009 · Cited by 948 · cited 1×
“In the Diabetes Prevention Program, CBT was extremely effective in reducing the progression to MS in subjects at risk of diabetes (43).”
Background
Cited by
Treatment of NAFLD with diet, physical activity and exercise
Romero-Gómez, M., Zelber-Sagi, S., & Trenell, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.016 · Cited by 1,347
Marchesini, G., Petta, S., & Dalle Grave, R. (2016) · Hepatology · doi:10.1002/hep.28392 · Cited by 292
Self-citationDigital Therapeutics: An Integral Component of Digital Innovation in Drug Development
Sverdlov, O., van Dam, J., Hannesdottir, K., & Thornton‐Wells, T. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1036 · Cited by 147
Stine, J. G., Long, M. T., Corey, K. E., Sallis, R. E., Allen, A. M., Armstrong, M. J., Conroy, D. E., Cuthbertson, D. J., Duarte-Rojo, A., Hallsworth, K., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000108 · Cited by 89
“[114] Cognitive behavioral therapy is an additional technique that has also been used successfully in patients with NAFLD to increase physical activity, with gains in fitness and loss of body weight that can persist for up to 2 years.[115] Lifestyle intervention based on social-cognitive theory, which explains how an…”
MethodSelf-citationWhich treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?
Mazzotti, A., Caletti, M. T., Marchignoli, F., Forlani, G., & Marchesini, G. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2016.12.028 · Cited by 46
Self-citationPetroni, M. L., Brodosi, L., Armandi, A., Marchignoli, F., Bugianesi, E., & Marchesini, G. (2023) · Nutrients · doi:10.3390/nu15030792 · Cited by 12
Self-citation
Metadata
- Authors
- Moscatiello, S., Di Luzio, R., Bugianesi, E., Suppini, A., Hickman, I. J., Di Domizio, S., Dalle Grave, R., & Marchesini, G.
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2011-04
- Volume
- 19
- Issue
- 4
- Pages
- 763-770
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W2077540482
- Cited by
- 57
- References
- 18
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.